Program Description & Educational Objectives

In this activity, experts in insulin-dependent diabetes discuss the optimal management of patients in long-term care settings.

Upon completion of this activity, participants will be able to:

• Demonstrate the ability to translate knowledge of hyperglycemia treatment, including the benefits and risks, evidence-based management strategies, and practice guidelines in the LTC setting
• Improve the ability of LTC practitioners to employ collaborative team care techniques and utilize all available resources to provide consistent clinical practices and improve diabetes care in the LTC population
• Demonstrate improved patient outcomes, representing a reduction/closure of diabetes healthcare performance gaps (A1C, glycemic control, SSI therapy) in the regionally defined care systems

Target Audience

This activity has been designed to meet the educational needs of US physicians, medical directors, physician assistants, consultant pharmacists, nurse practitioners, nurses, and other healthcare professionals who are active in the management of patients with insulin-dependent diabetes.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: February 18, 2010 - February 17, 2011
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

All faculty AND staff involved in the planning or presentation of continuing education activities sponsored/provided by Purdue University School of Pharmacy are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

Course Director and Moderator

Derek LeRoith, MD, PhD
Professor of Medicine, Endocrinology, Diabetes and Bone Disease
Mt. Sinai School of Medicine
New York, New York

Derek LeRoith, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant for AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc; and Takeda Pharmaceuticals North America, Inc.

Speakers Bureau participant with AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc; and Takeda Pharmaceuticals North America, Inc.

Advisory Board for AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Merck & Co., Inc.; and sanofi-aventis.

Interviewees

Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana

Lawrence Blonde, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Amylin Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; MannKind Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer Inc; Roche Laboratories Inc.; and sanofi-aventis.

Honoraria from Amylin Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Halozyme Therapeutics; LifeScan, Inc.; MannKind Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer Inc; Roche Laboratories Inc.; sanofi-aventis; and VeroScience LLC.

Other Financial or Material Support from spouse, who is a stock shareholder in Amylin Pharmaceuticals, Inc. and Pfizer Inc in an account that is not part of their community property.

Charles A. Cefalu, MD, MS
Professor of Internal Medicine
Director, Geriatric Medicine Program
Co-Director, Center on Aging
Louisiana State University
New Orleans, Louisiana

Charles A. Cefalu, MD, MS, currently has no financial interests/relationships or affiliations in relation to this activity.

Content Director

Annette Wiggins
PVI, PeerView Institute for Medical Education, Inc.

Annette Wiggins currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University School of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University School of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education is approved as a provider of continuing nursing education by the Indiana State Nurses Association. ISNA is accredited as an approver of continuing education in nursing by the Commission on Accreditation of the American Nurses Credentialing Center. Code #CNEP-09-21.

This program has been approved for 1.0 contact hour(s).

This CME/CNE/CPE activity is jointly sponsored by Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.